Journal of Diabetes and Its Complications
Volume 17, Issue 2 , Pages 90-97 , March 2003

Improvement in quality of diabetes control and concentrations of AGE-products in patients with type 1 and insulin-treated type 2 diabetes mellitus studied over a period of 10 years (JEVIN)

  • Ralf Schiel

      Affiliations

    • Department of Internal Medicine II, University of Jena Medical School, Jena, Germany
    • Department of Ophthalmology, University of Jena Medical School, Jena, Germany
    • Corresponding Author InformationCorresponding author. Department of Internal Medicine II, University of Jena Medical School, D-07740 Jena, Germany. Tel.: +49-3641-939769; fax: +49-3641-939639
    • ,
  • Sybille Franke

      Affiliations

    • Department of Internal Medicine IV, University of Jena Medical School, Jena, Germany
    • ,
  • Thilo Appel

      Affiliations

    • Department of Internal Medicine IV, University of Jena Medical School, Jena, Germany
    • ,
  • Ulrich Voigt

      Affiliations

    • Department of Clinical Biochemistry, University of Aberdeen Medical School, Aberdeen, UK
    • ,
  • Iain S. Ross

      Affiliations

    • Roche Diagnostics GmbH, Penzberg, Germany
    • ,
  • Rosemarie Kientsch-Engel

      Affiliations

    • Roche Diagnostics GmbH, Penzberg, Germany
    • ,
  • Günter Stein

      Affiliations

    • Department of Internal Medicine IV, University of Jena Medical School, Jena, Germany
    • ,
  • Ulrich A. Müller

      Affiliations

    • Department of Internal Medicine II, University of Jena Medical School, Jena, Germany
    • Department of Ophthalmology, University of Jena Medical School, Jena, Germany

Received 29 May 2002 ,Accepted 12 July 2002.

References 

  1. Berger M, Grüßer M, Jörgens V, Kronsbein P, Mühlhauser I, Scholz V, et al. Behandlungs-und Schulungsprogramm für Typ-II-Diabetiker, die Insulin spritzen. Cologne, Germany: Deutscher Ärzte-Verlag; 1994;
  2. Bierhaus A, Hofmann MA, Ziegler R, Nawroth PP. AGE and their interaction with AGE-receptors in vascular disease and diabetes: I. The AGE concept. Cardiovascular Research. 1998;37:586–600
  3. Boel E, Selmer J, Flodgaard HJ, Jensen T. Diabetic late complications: will aldose reductase inhibitors or inhibitors of advanced glycosylation end-product formation hold promise?. Journal of Diabetes and its Complications. 1995;9:104–129
  4. Brownlee A. Advanced protein glycosylation in diabetes aging. Annual Review of Medicine. 1995;46:223–234
  5. Bucala R, Vlassara H. Advanced glycosylation end products in diabetic renal and vascular disease. American Journal of Kidney Diseases. 1995;26:875–888
  6. Early Treatment Diabetic Retinopathy Study Group . Ophthalmology. 1991;98(Suppl. 5):23
  7. Friedman EA. Advanced glycosylated end-products and hyperglycaemia in the pathogenesis of diabetic complications. Diabetes Care. 1999;22:B65–B71
  8. Grüßer M, Hartmann P, Jörgens V. Behandlungs-und Schulungsprogramm für Typ-1-Diabetiker. Mainz, Germany: Verlag Kirchheim; 1996;
  9. Grüßer M, Jörgens V, Berger M. Vor dem essen Insulin. Für die flexible Behandlung des Typ-2-Diabetes mit Normalinsulin. Mainz, Germany: Kirchheim-Verlag; 1999;
  10. Guidelines Subcommittee . 1999 World Health Organization—International Society of Hypertension Guidelines for the Management of Hypertension. Journal of Hypertension. 1999;17:151–183
  11. Jackson JL. The German health system. Lessons for reform in the United States. Archives of Internal Medicine. 1997;157:155–160
  12. Kassenärztliche Vereinigung Thüringen (1998). Modellversuch Vereinbarung über eine strukturierte und qualitätsgesicherte ambulante Versorgung von Patienten mit Diabetes mellitus zwischen der Kassenärztlichen Vereinigung Thüringen und der AOK Thüringen. Germany, Anlage 3, RS III/1998.
  13. Larkins RG, Dunlop ME. The link between hyperglycaemia and diabetic nephropathy. Diabetologia. 1992;35:499–504
  14. Liniger C, Albeanu A, Bloise D, Assal JP. The tuning fork revisited. Diabetic Medicine. 1990;7:859–864
  15. Masaki H, Okano Y, Sakurai H. Generation of oxygen species from AGE during ultraviolet light (UVA) irradiation and a possible mechanism for cell damage. Biochimica et Biophysica Acta. 1999;1428:45–46
  16. Müller UA, Ross IS, Klinger H, Geisenheiner S, Chantelau EA. Quality of centralized diabetes care: a population-based study in the German Democratic Republic 1989–1990. Acta Diabetologica. 1993;30:166–172
  17. Odetti P, Pronzato MA, Noberasco G, Cosso L, Traverso N, Cottalasso D. Relationship between glycation and oxidation related fluorescence in rat collagen during aging. An in vivo and in vitro study. Journal of Laboratory Investigations. 1994;70:61–67
  18. Raj DS, Choudhury D, Welbourne TC, Levi M. AGE: a nephrologist's perspective. American Journal of Kidney Diseases. 2000;35:365–380
  19. Schiel R, Braun A, Rillig A, Voigt U, Ross IS, Müller UA. Improvement of the quality of diabetes care—JEVIN, a population-based survey with 10-years-follow-up: 1989/90–1999/2000. Abstract Diabetologia. 2001;44:A247
  20. Schiel R, Müller C, Müller UA. Verbesserung der Stoffwechseleinstellung und Änderung des Einweisungsverhalten zur stationären Behandlung von Patienten mit Diabetes mellitus nach Einführung strukturierte Fortbildungsseminare für Ärzte—Eine prospektive Studie 1992–1998. Abstract Diabetes und Stoffwechsel. 2002;
  21. Schiel R, Müller UA. Intensive or conventional insulin therapy in type 2 diabetic patients? A population-based study on metabolic control and quality of life (The JEVIN-trial). Experimental and Clinical Endocrinology & Diabetes. 1999;107:506–511
  22. Schiel R, Müller UA, Sprott H, Schmelzer A, Hunger-Dathe W, Mertes B, et al. Änderungen der Behandlungsqualität bei Patienten mit Typ-1-Diabetes fünf Jahre nach Verabschiedung der St. Vincent-Deklaration-Die JEVIN-Studie. Diabetes und Stoffwechsel. 1997;6:239–244
  23. Schiel R, Müller UA, Sprott H, Schmelzer A, Mertes B, Hunger-Dathe W, et al. The JEVIN-trial: a population-based survey on the quality of diabetes care in Germany—1994/95 compared to 1989/90. Diabetologia. 1997;40:1350–1357
  24. Schleicher ED, Wagner E, Nerlich AG. Increased accumulation of the glycoxidation product Nε-(carboxymethyl)lysine in human tissues in diabetes and aging. Journal of Clinical Investigations. 1997;99:457–468
  25. Schulz B, Bibergeil H, Rybka J, Koev D. Strategy and structure of diabetes health care in some European Socialist countries. In:  Krall LP editors. World book of diabetes in practice. 3:Amsterdam, The Netherlands: Elsevier; 1988;p. 375–376
  26. Singh R, Barden A, Mori T, Beilin L. Advanced glycation end-products: a review. Diabetologia. 2001;44:129–146
  27. The Diabetes Control and Complications Trial Research Group . The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. New England Journal of Medicine. 1993;329:977–986
  28. Ulrich P, Zhang X. Pharmacological reversal of advanced glycation end-product-mediated protein crosslinking. Diabetologia. 1997;40:S157–S159
  29. Vlassara H, Bucala R, Striker L. Biology of disease. Pathogenic effects of advanced glycosylation: biochemical, biologic, and clinical implications for diabetes and aging. Journal of Laboratory Investigations. 1994;70:138–151
  30. World Health Organization (1985). Diabetes mellitus. Technical report series 727. WHO, Geneva, Switzerland.
  31. Young MJ, Boulton AJM, Macleod AF, Williams DRR, Sonksen PH. A multicentre study of the prevalence of diabetic peripheral neuropathy in the United Kingdom hospital clinic population. Diabetologia. 1993;36:150–154

PII: S1056-8727(02)00203-9

Journal of Diabetes and Its Complications
Volume 17, Issue 2 , Pages 90-97 , March 2003

Article Tools

* Image Usage & Resolution